Literature DB >> 25277793

Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens.

Joseph E Tota1, Agnihotram V Ramanakumar2, Luisa L Villa3, Harriet Richardson4, Ann N Burchell5, Anita Koushik6, Marie-Hélène Mayrand7, François Coutlée8, Eduardo L Franco9.   

Abstract

It has been hypothesized that, following a reduction in human papillomavirus (HPV) vaccine-targeted genotypes, an increase in prevalence of other HPV types may occur due to reduced competition during natural infection. Any apparent postvaccination increase must be distinguished from diagnostic artifacts consequent to consensus PCR assays failing to detect HPV types present in low copy numbers in coinfected specimens (under the assumption that with a drop in vaccine-preventable types there may be increased detection of previously "masked" types). We reanalyzed anogenital specimens to evaluate unmasking of HPV52 that may be caused by elimination of HPV16. Using highly sensitive type-specific real-time HPV52 PCR, we retested 1,200 anogenital specimens (all HPV52 negative according to consensus PCR assays) from six epidemiologic studies (200 specimens/study; 100 HPV16(+)/study). Multivariate logistic regression, with adjustment for age and number of sexual partners, was used to evaluate the association between HPV16 positivity and detection of HPV52. In our pooled analysis (n = 1,196), the presence of HPV16 was positively associated with HPV52 detection [adjusted OR, 1.47; 95% confidence interval (CI), 0.76-2.82]. In our separate (study specific) analyses, a statistically significant association was observed in one study that included HIV-infected males (HIPVIRG study; adjusted OR, 3.82; 95% CI, 1.19-12.26). We observed a positive association between HPV16 viral load (tertiles) and detection of HPV52 (P for trend = 0.003). These results indicate that diagnostic artifacts, resulting from unmasking of HPV52, may occur in some settings in the evaluation of HPV type replacement. Additional studies exploring the extent and severity of unmasking are needed. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25277793      PMCID: PMC4295012          DOI: 10.1158/1055-9965.EPI-14-0566

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  21 in total

1.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Authors:  Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma Paavonen; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Henry Kitchener; Júlio C Teixeira; S Rachel Skinner; Unnop Jaisamrarn; Genara Limson; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Diane M Harper; Warner Huh; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Gary Dubin; Matti Lehtinen
Journal:  Lancet Oncol       Date:  2011-11-08       Impact factor: 41.316

2.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

3.  Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality.

Authors:  Melinda Butsch Kovacic; Philip E Castle; Rolando Herrero; Mark Schiffman; Mark E Sherman; Sholom Wacholder; Ana C Rodriguez; Martha L Hutchinson; M Concepción Bratti; Allan Hildesheim; Jorge Morales; Mario Alfaro; Robert D Burk
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

4.  Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys.

Authors:  Salvatore Vaccarella; Silvia Franceschi; Peter J F Snijders; Rolando Herrero; Chris J L M Meijer; Martyn Plummer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

5.  Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; François Coutlée; Isabel Rodrigues; Stephen D Walter; Sam Ratnam; Eduardo L Franco
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

6.  Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study.

Authors:  Salvatore Vaccarella; Martyn Plummer; Silvia Franceschi; Patti Gravitt; Mary Papenfuss; Danelle Smith; Luisa Villa; Eduardo Lazcano Ponce; Anna R Giuliano
Journal:  J Infect Dis       Date:  2011-09-09       Impact factor: 5.226

7.  Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers.

Authors:  Seiichiro Mori; Sari Nakao; Iwao Kukimoto; Rika Kusumoto-Matsuo; Kazunari Kondo; Tadahito Kanda
Journal:  Cancer Sci       Date:  2011-03-30       Impact factor: 6.716

8.  Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study.

Authors:  Alexandra de Pokomandy; Danielle Rouleau; George Ghattas; Sylvie Vézina; Pierre Coté; John Macleod; Guy Allaire; Eduardo L Franco; François Coutlée
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

9.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

10.  Human papillomavirus infections among couples in new sexual relationships.

Authors:  Ann N Burchell; Pierre-Paul Tellier; James Hanley; François Coutlée; Eduardo L Franco
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

View more
  14 in total

1.  Human Papillomavirus Viral Load and Transmission in Young, Recently Formed Heterosexual Couples.

Authors:  Michel D Wissing; Karolina Louvanto; Emilie Comète; Ann N Burchell; Mariam El-Zein; Allita Rodrigues; Pierre-Paul Tellier; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

2.  Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.

Authors:  Joseph E Tota; Frank Struyf; Marko Merikukka; Paula Gonzalez; Aimée R Kreimer; Dan Bi; Xavier Castellsagué; Newton S de Carvalho; Suzanne M Garland; Diane M Harper; Naveen Karkada; Klaus Peters; Willy A J Pope; Carolina Porras; Wim Quint; Ana Cecilia Rodriguez; Mark Schiffman; John Schussler; S Rachel Skinner; Júlio Cesar Teixeira; Cosette M Wheeler; Rolando Herrero; Allan Hildesheim; Matti Lehtinen
Journal:  J Natl Cancer Inst       Date:  2017-01-28       Impact factor: 13.506

3.  Capturing multiple-type interactions into practical predictors of type replacement following human papillomavirus vaccination.

Authors:  Irene Man; Kari Auranen; Jacco Wallinga; Johannes A Bogaards
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

4.  Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Luisa L Villa; Harriet Richardson; Ann N Burchell; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2016-06-02       Impact factor: 5.226

5.  Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.

Authors:  Ross L Cameron; Kimberley Kavanagh; Jiafeng Pan; John Love; Kate Cuschieri; Chris Robertson; Syed Ahmed; Timothy Palmer; Kevin G J Pollock
Journal:  Emerg Infect Dis       Date:  2016-01       Impact factor: 6.883

6.  Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination.

Authors:  Joseph E Tota; Mengzhu Jiang; Agnihotram V Ramanakumar; Stephen D Walter; Jay S Kaufman; François Coutlée; Harriet Richardson; Ann N Burchell; Anita Koushik; Marie Hélène Mayrand; Luisa L Villa; Eduardo L Franco
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

Review 7.  Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.

Authors:  David Mesher; Kate Soldan; Matti Lehtinen; Simon Beddows; Marc Brisson; Julia M L Brotherton; Eric P F Chow; Teresa Cummings; Mélanie Drolet; Christopher K Fairley; Suzanne M Garland; Jessica A Kahn; Kimberley Kavanagh; Lauri Markowitz; Kevin G Pollock; Anna Söderlund-Strand; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Elizabeth Unger; Sara L Thomas
Journal:  Emerg Infect Dis       Date:  2016-10       Impact factor: 6.883

8.  HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples.

Authors:  Alyssa M Cornall; Marin Poljak; Suzanne M Garland; Samuel Phillips; Dorothy A Machalek; Jeffrey H Tan; Michael A Quinn; Sepehr N Tabrizi
Journal:  Papillomavirus Res       Date:  2017-10-18

9.  Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.

Authors:  Ingrid Baasland; Pål R Romundstad; Maj Liv Eide; Christine M Jonassen
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

10.  Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population.

Authors:  Pamela Moussavou-Boundzanga; Ismaël Hervé Koumakpayi; Ingrid Labouba; Eric M Leroy; Ernest Belembaogo; Nicolas Berthet
Journal:  Virol J       Date:  2017-12-21       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.